Congestive Heart Failure (CHF) Epidemiology Forecast 2025-2034

Heart failure (HF) is a complex syndrome characterized by severe symptoms, multiple signs, and associated comorbidities. It continues to be a significant clinical and public health challenge, impacting around 1% to 2% of the adult population.

Congestive Heart Failure (CHF) Epidemiology Forecast Report Coverage

The “Congestive Heart Failure (CHF) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of congestive heart failure (CHF). It projects the future incidence and prevalence rates of congestive heart failure (CHF) across various populations. The study covers age, gender, and type as major determinants of the congestive heart failure (CHF)-affected population. The report highlights patterns in the prevalence of congestive heart failure (CHF) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of congestive heart failure (CHF) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Congestive Heart Failure (CHF) Disease Overview

Congestive heart failure (CHF) is a chronic condition in which the heart cannot pump blood effectively, resulting in an inadequate supply to meet the body’s needs. It often develops due to underlying issues like coronary artery disease, high blood pressure, or heart valve disorders. Common symptoms include shortness of breath, fatigue, and fluid buildup, leading to swelling in the legs, ankles, or abdomen. CHF significantly affects quality of life and demands continuous management to mitigate its progression and complications.

Congestive Heart Failure (CHF): Treatment Overview

Congestive heart failure (CHF) treatment aims to manage symptoms, enhance quality of life, and slow disease progression. It often includes lifestyle changes like a heart-healthy diet, regular physical activity, and fluid management, combined with medications such as diuretics, ACE inhibitors, beta-blockers, and others to support heart function. For severe cases, advanced options like implantable devices, ventricular assist devices, or heart transplants may be necessary. Treatment is also being personalized to address the underlying causes and coexisting conditions.

Epidemiology

The congestive heart failure (CHF) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for congestive heart failure (CHF) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for congestive heart failure (CHF) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Globally, heart failure affects approximately 26 million people, highlighting its significant impact on public health. In the United States alone, around 6.5 million individuals are living with heart failure, with more than 960,000 new cases diagnosed each year
• A study indicated that individuals with congestive heart failure have a shorter life expectancy by 10 years when compared to those without the condition.
• Another study revealed that survival rates for individuals with chronic heart failure are relatively high in the short term but decline over time. Approximately 80% to 90% survive the first year, 50% to 60% reach five years, and only 30% survive up to 10 years.
• A study conducted in the United States revealed that the lifetime risk of heart failure has risen to 24%, meaning that roughly 1 in 4 individuals will develop the condition during their lifetime.

Country-wise Congestive Heart Failure (CHF) Epidemiology

The congestive heart failure (CHF) epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of congestive heart failure (CHF) varies between countries owing to the differences in factors such as obesity, tobacco smoking, diabetes and others. According to the U.S. Centers for Disease Control and Prevention, in the United States, approximately 6.7 million adults aged 20 and older are living with heart failure. Also, in 2022, heart failure was referenced on 457,212 death certificates which accounted for 13.9% of all deaths in the nation.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of congestive heart failure (CHF) based on several factors.
• Congestive Heart Failure (CHF) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of congestive heart failure (CHF) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of congestive heart failure (CHF) epidemiology in the 8 major markets?
• What will be the total number of patients with congestive heart failure (CHF) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of congestive heart failure (CHF) in the 8 major markets in the historical period?
• Which country will have the highest number of congestive heart failure (CHF) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of congestive heart failure (CHF) during the forecast period of 2025-2034?
• What are the currently available treatments for congestive heart failure (CHF)?
• What are the disease risks, signs, symptoms, and unmet needs of congestive heart failure (CHF)?

This product will be delivered within 3-5 business days.